Halozyme Therapeutics Bids to Acquire German Competitor Evotec
Halozyme Therapeutics submitted a bid to acquire German drug developer Evotec in a deal with an equity value of 2 billion euros ($2.11 billion.) ...
SDxCentral1h
Halozyme Proposes €2 Billion Acquisition of Evotec at €11 Per Share
Combination Would Create a Global Innovative Services Company with a Unique Set of Differentiated Technologies, a Deep Pipeline, and Best-in-class Industry Team Storage-Area Networking (SAN) DIEGO, ...
Le Lézard2h
Halozyme Confirms Proposal to Combine with Evotec for ?11.00 Per Share in an All-Cash Transaction
Halozyme Therapeutics, Inc. ("Halozyme" or the "Company") confirmed it has submitted a non-binding proposal to the Management Board and Supervisory Board of Evotec SE ("Evotec") to acquire Evotec for ...
Halozyme makes 2 billion euro buyout offer for drug developer Evotec
Halozyme intends to purchase all the shares of Evotec at 11 euros per share, which represents a premium of 27.5% to Evotec's last close price. U.S.-listed shares of Evotec were up 6.3%, while those of ...
Germany’s Evotec Gets Takeover Interest From Halozyme
Germany’s Evotec SE has attracted takeover interest from Nasdaq-listed biotech firm Halozyme Therapeutics Inc. for a deal ...
Halozyme weighing buyout of drugmaker Evotec, Bloomberg News reports
German drugmaker Evotec is attracting takeover interest from U.S.-based Halozyme Therapeutics , Bloomberg News reported on Thursday.
Evotec jumps on report Halozyme expressed takeover interest
ADRs quickly rose 14% on a report that Halozyme Therapeutics (HALO) has expressed takeover interest. Halozyme has recently ...